{
    "clinical_study": {
        "@rank": "38304", 
        "arm_group": [
            {
                "arm_group_label": "olive oil with 10% d-limonene", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Topical spray one-time administration 2 puffs of 100\u00b5l"
            }, 
            {
                "arm_group_label": "AV2-DM antiviral spray", 
                "arm_group_type": "Experimental", 
                "description": "Topical spray one-time application 2 puffs of 100\u00b5l"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an\n      effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV)\n      infection.\n\n        -  Primary endpoint: significant drop in viral load AV2-DM versus placebo\n\n        -  Secondary endpoint:the number of patients with adverse events"
        }, 
        "brief_title": "AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Genital Human Papilloma Virus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Papilloma", 
                "Virus Diseases", 
                "Warts", 
                "Papillomavirus Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women between 25 and 40 years\n\n          2. Patient has been recently (up to 6 months) Quantitatively (Viral Load) and\n             Qualitatively (HPV types) diagnosed with HPV.\n\n          3. Ability and willingness to participate in the study.\n\n          4. Subject agrees to refrain from using prescription or supplemental antiviral\n             medications without obtaining permission of the Treating Doctor.\n\n          5. Voluntary written informed consent.\n\n        Exclusion Criteria:\n\n          1. Subject has been vaccinated against HPV\n\n          2. Interval between a delivery and T0 is less than 3 months\n\n          3. Subject has a gynecologic surgical intervention between T0 and T1\n\n          4. Subject is diagnosed HPV negative at T0\n\n          5. Subject has a (adeno)carcinoma in situ.\n\n          6. Females with child bearing potential who are not using a reliable, medically accepted\n             method of birth control\n\n          7. Pregnant or breast-feeding female, or women planning to become pregnant during the\n             trial.\n\n          8. Medical history of immunosuppression by radiotherapy, chemotherapy, immuno-modulatory\n             drugs, or HIV.\n\n          9. Participation to another clinical trial concerning HPV infections within 6 months\n             before the application of AV2-DM antiviral spray.\n\n         10. Medical history of any severe diseases like hepatitis, renal or liver dysfunction,\n             car-diovascular, gastrointestinal, malignant tumor(s), or psychiatric disorders etc.,\n             which might influence the assessments or conduct of the trial by the discretion of\n             the investigator.\n\n         11. Intake or application of antivirals or other prohibited concomitant medication within\n             30 days prior to application of AV2, or patients who plan to take such drugs during\n             the trial.\n\n         12. Known or suspected allergic or adverse response to the investigational product AV2-DM\n             Antiviral spray, it's components, olive oil or d-limonene.\n\n         13. Inability to follow the study protocol."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654822", 
            "org_study_id": "AV2-HPV-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "AV2-DM antiviral spray", 
                "description": "one time (2 puffs) topical application of 100\u00b5l AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix", 
                "intervention_name": "topical application cervical spray", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "olive oil with 10% d-limonene", 
                "description": "one time (2 puffs) topical spray of 100 \u00b5l (90% olive oil and 10% d-limonene) on the cervix", 
                "intervention_name": "topical spray on the cervix", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AV2-DM antiviral spray", 
                "intervention_name": "cervical swab  with Cervex-Brush-Combi at T0", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "AV2-DM antiviral spray", 
                "intervention_name": "cervical swab  with Cervex-Brush-Combi at T1", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "olive oil with 10% d-limonene", 
                "intervention_name": "cervical swab  with Cervex-Brush-Combi at T0", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "olive oil with 10% d-limonene", 
                "intervention_name": "cervical swab  with Cervex-Brush-Combi at T1", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antiviral Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HPV", 
            "cervix"
        ], 
        "lastchanged_date": "November 8, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerpen", 
                    "country": "Belgium", 
                    "zip": "2020"
                }, 
                "name": "Labo Riatol"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Efficacy comparison number of patients with drop (min 2 Log units) in HPV specific viral load AV2-DM versus placebo", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654822"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "number of adverse vents AV2-DM versus placebo", 
            "safety_issue": "Yes", 
            "time_frame": "90 days"
        }, 
        "source": "Cesa Projects International", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cesa Projects International", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}